Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Multi-Cycle Product Review Analysis To Begin In Fiscal 2004

Executive Summary

FDA expects an analysis of the "root causes" of multi-cycle product reviews to begin in fiscal year 2004, Office of New Drugs Director John Jenkins, MD, said June 24 during the Biotechnology Industry Organization annual meeting in Washington, D.C

Related Content

Complete Submissions Are Key To Good Review Management Principles – FDA
Good Review Management Guidance To Be Tested By “Root Causes” Analysis
FDA First-Cycle Approval Rate For NMEs Leaps To 50% In 2003
FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
FDA Defines Good Review Management; No Data In Labeling Negotiations
Multi-cycle product reviews
FDA Has “Issues” With NDAs; Half Of 74-Day Letters Note Application Flaws
NDA Reviews To Be Studied Prospectively To Identify Best First-Cycle Practices
FDA Emphasizing Written Communication With Sponsors On Pending NDAs
McKesson Splits CEO Into Operations & Strategy: Hammergren & Mahoney



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts